Stocks · News reference
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
Dow Jumps 200 Points; US Trade Deficit Widens In August
U.S. stocks rose Tuesday, led by Nasdaq and S&P 500, while August’s trade deficit hit $105.6B. Utilities gained; energy and oil fell.